2197 — Clover Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- HK$3.48bn
- HK$3.05bn
- CNY38.42m
Annual cashflow statement for Clover Biopharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -913 | -6,016 | -2,452 | -139 | -903 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 31.5 | 178 | 636 | 1,814 | 728 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1,353 | 4,896 | 65.1 | -2,478 | -154 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 477 | -918 | -1,691 | -728 | -288 |
| Capital Expenditures | -114 | -80.3 | -106 | -9.18 | -1.63 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -280 | 192 | 68.1 | 3.02 | 4.8 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -394 | 112 | -37.5 | -6.16 | 3.17 |
| Financing Cash Flow Items | -0.327 | -159 | -235 | -130 | 194 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 317 | 3,057 | 483 | -142 | -51.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 367 | 2,251 | -1,160 | -872 | -335 |